Low dose oral idarubicin in combination with cyclophosphamide and dexamethasone (CID) for management of melphalan-prednisolone (MP) resistant myeloma

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Leukemia & lymphoma 1999-04, Vol.33 (3-4), p.407
Hauptverfasser:	Kashyap, S, Ganguly, K, Bardhan, G, Majumdar, G
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Adult Aged Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Cyclophosphamide - administration & dosage Cyclophosphamide - adverse effects Dexamethasone - administration & dosage Dexamethasone - adverse effects Drug Resistance, Neoplasm Female Humans Idarubicin - administration & dosage Idarubicin - adverse effects Male Middle Aged Multiple Myeloma - blood Multiple Myeloma - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!